Lupin Limited announced that its step-down subsidiary, Multicare Pharmaceuticals Philippines, Inc. (MPPI), has completed the buyback of 30,559 shares. Consequently, effective October 1, 2026, MPPI has become a wholly owned subsidiary of Nanomi B.V., the Netherlands.

Nanomi B.V. is a wholly owned subsidiary of Lupin Limited. The completion of this transaction follows an earlier intimation provided to stock exchanges on July 1, 2026, regarding the ongoing process of acquiring the balance shares held by minority shareholders.

Regulatory Disclosure Details

The company filed this disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirms that the acquisition of the remaining equity stake transforms MPPI's status within the corporate structure.

Corporate Structure Implications

The move simplifies the ownership structure of the Philippine operations. By eliminating minority interests, Lupin consolidates full control over MPPI through its Dutch subsidiary, Nanomi B.V. This structural change does not involve any external capital infusion or debt restructuring as per the disclosure.

The buyback was executed by MPPI itself, targeting the specific block of 30,559 shares that remained outside the group's control. With this transaction closed, there are no remaining external shareholders in Multicare Pharmaceuticals Philippines, Inc.

Lupin Limited announced on September 28, 2026, that it has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its New Drug Application for Apixaban Oral Suspension 1.25mg/mL.

The product was approved via the 505(b)(2) regulatory pathway. This oral liquid formulation of apixaban serves as an alternative administration option for adult patients requiring anticoagulation therapy, specifically targeting those who may have difficulty swallowing tablets.

Product differentiation and market positioning

Apixaban is the active ingredient in Eliquis®, a drug marketed by Bristol Myers Squibb. Lupin's new formulation expands the ways in which this important therapy can be administered. The company stated that this development reinforces its commitment to building a differentiated portfolio that addresses meaningful patient needs.

Vinita Gupta, CEO of Lupin, noted that the tentative approval reflects the company's continued focus on developing medicines that solve specific clinical challenges. The move positions Lupin to capture demand in segments underserved by standard tablet formulations.

Manufacturing and operational readiness

Upon receiving final approval, the product will be manufactured at Lupin's facility in Somerset, New Jersey. This location leverages the company's U.S.-based manufacturing expertise to ensure high-quality standards and supply reliability for the American market.

About Lupin's global footprint

Lupin is a global pharmaceutical leader headquartered in Mumbai with products distributed in over 100 markets. The company maintains a diversified portfolio spanning generics, complex generics, specialty medicines, and biosimilars. It holds strong leadership positions in the U.S. and India across core therapeutic areas including cardiovascular, respiratory, diabetes, gastrointestinal, and women's health.

The company operates 15 state-of-the-art manufacturing facilities and employs over 26,000 professionals. Its infrastructure includes six research centers dedicated to sustainable operations and innovation in diagnostics, digital health, and patient-support programs.